You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
TeamChip for High-throughput, Predictive Human Metabolism and Toxicology
SBC: Solidus Biosciences, Inc. Topic: NIEHSDESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with Rensselaer Polytechnic Institute is proposing to address a critical need in chemical safety technology through its proprietary Transfected Enzyme and Metabolism Chip (or TeamChip) for high-throughput analysis of systematic drug candidate and chemical metabolism and toxicology. The TeamChip is being developed to mi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Novel Optical Microprobes for Ultra-Precise Intraocular Laser Surgery
SBC: PhotonTech, LLC Topic: NEIDESCRIPTION (provided by applicant): This STTR project proposes to develop a novel optical scalpel for ultra-precise ophthalmic laser surgery. Segmentation and removal of epiretinal membranes during vitreoretinal surgery is currently performed mechanically with both blunt and sharp dissection, which causes collateral damage to healthy retinal tissue. Conventional fiber-based surgical laser micropr ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Topical Nanoparticles for CNV
SBC: NANOTRANS TECHNOLOGIES, INC. Topic: NEIDESCRIPTION (provided by applicant): Age Related Macular Degeneration (AMD) is the leading cause of blindness in adults over 50 years. Choroidal neovascularization (CNV), the pathologic creation of new blood vessels in the choroid layer of the eye, is a principal cause of blindness due to AMD. Current therapeutic management of AMD is far from optimal and requires repeated injections in the vitreou ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Protein Therapeutic Formulations
SBC: SOLUBLE THERAPEUTICS, INC Topic: NIGMSDESCRIPTION (provided by applicant): This proposal involves the development and validation of a novel approach to improve and accelerate the discovery of biopharmaceuticals (i.e. vaccines, monoclonal antibodies and other therapeutic proteins). Biopharmaceuticals are used to treat a variety of infectious and chronic diseases. The proposed research is intended to establish a new paradigm for rapidly ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Intensity-Based Scoring of Macromolecule Crystallization Plates
SBC: iXpressGenes, Inc. Topic: NIGMSDESCRIPTION (provided by applicant): Crystallization, followed by subsequent structure determination, is a major step in understanding the structure-function relationship of macromolecules. Understanding macromolecule structure has become a key part in the development of new pharmaceuticals, and is a major area of NIH research. Crystallization however is also the rate limiting step, despite techn ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Numerical Tools for Predicting Drug Dissolution Profiles
SBC: RES Group, Inc. Topic: NIGMSDESCRIPTION (provided by applicant): This STTR Phase I proposal describes the development of a modeling framework that combines a mesoscopic model for hydrodynamics with dissolution kinetic models in order to accurately describe the dissolution behavior of drugs. The complexities of the drug dissolution problem have led to the development of empirical methodologies being the widespread practice in ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Rapid isolation of high-affinity human antibodies from large synthetic libraries
SBC: VYBION, INC. Topic: NIGMSDESCRIPTION (provided by applicant): With over 300 therapeutic proteins currently in various stages of clinical trials, the road to a healthier future will require new methods for producing safer and less expensive recombinant proteins. In particular, next generation therapeutics derived from monoclonal antibodies (e.g. Fab, scAb, scFv, immunotoxins, etc) show great clinical promise in treating a ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Sensor Network for Monitoring Real-world Arm Activity of Rehabilitation Patients
SBC: ACTIVE WAVE, INC. Topic: NICHDDESCRIPTION (provided by applicant): Evidence and theory indicate that laboratory measures of impairment and function do not predict how older adults actually function in daily life. Thomas Glass (1998), for example, reports marked differences between functional activities that community residents can do and do do in survey data from the MacArthur Studies of Successful Aging. Therefore, subst ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Oral Agents to Stimulate Neutrophil Production
SBC: Phoenicia Biosciences, Inc. Topic: NHLBIDESCRIPTION (provided by applicant): Phoenicia Biosciences, Inc. scientists have discovered a small family of low MW compounds (short-chain fatty acid derivatives (SCFADs) - designated Hemokines ) that stimulate proliferation of human hematopoietic progenitors, multi-lineage-hematopoietic cell lines, and have increased red blood cell counts in animal models, with oral administration. Recently, se ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule targeting of NADPH oxidase in neutrophils
SBC: P2D, INC Topic: NHLBIDESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health